Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBFPO1)

Drug Name

F-8-IL-10 fusion protein Drug Info

Synonyms

Dekavil; F-8-IL-10; F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis); F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis), Philogen

Indication

Disease Entry	ICD 11	Status	REF
Endometriosis	GA10	Phase 2	[1]
Rheumatoid arthritis	FA20	Phase 2	[2]
Inflammatory bowel disease	DD72	Phase 1	[2]

Cross-matching ID

TTD Drug ID: DMBFPO1

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Interleukin-10 (IL10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AM0010	DMGMNUE	Pancreatic cancer	2C10	Phase 3	[4]
Ilodecakin	DMDNHRA	Sarcoidosis	4B20.5	Phase 2	[5]
XT-150	DMCYM9Q	Knee osteoarthritis	FA01	Phase 2	[6]
AG019	DMEN2L7	Type-1 diabetes	5A10	Phase 1/2	[7]
Ankinara	DMZKC7S	Inflammatory bowel disease	DD72	Investigative	[8]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-10 (IL10)	TTT0Q1F	IL10_HUMAN	Modulator	[3]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02270632) A Randomized, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of F8IL10 Dekavil) in Patients With Active RA Receiving MTX. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther. 2009;11(5):R142.
4	Clinical pipeline report, company report or official report of ARMO BioSciences.
5	Ilodecakin. Schering-Plough Corp. IDrugs. 1999 Oct;2(10):1045-58.
6	Clinical pipeline report, company report or official report of Xalud Therapeutics
7	ClinicalTrials.gov (NCT03751007) A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recently Diagnosed Type 1 Diabetes Mellitus (T1D). U.S. National Institutes of Health.
8	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.